NASDAQ:CLLS Cellectis Q1 2026 Earnings Report $2.84 +0.15 (+5.58%) Closing price 08/7/2026 03:49 PM EasternExtended Trading$2.84 0.00 (-0.18%) As of 08/7/2026 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cellectis EPS ResultsActual EPS-$0.18Consensus EPS -$0.26Beat/MissBeat by +$0.08One Year Ago EPSN/ACellectis Revenue ResultsActual Revenue$7.55 millionExpected Revenue$11.04 millionBeat/MissMissed by -$3.49 millionYoY Revenue GrowthN/ACellectis Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (6-K)Press ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Press Release Cellectis Earnings HeadlinesCellectis Reports Financial Results for the Second Quarter 2026August 6 at 4:30 PM | globenewswire.comMonthly information on share capital and company voting rightsAugust 5 at 4:30 PM | globenewswire.comChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low. Beijing's central bank has bought gold for 20 straight months, its longest streak in a decade. Goldman Sachs estimates China's real gold buying is 4.8 times the official figure. The European Central Bank confirms gold has overtaken US Treasuries as the world's top reserve asset, at 27% versus 22%. As foreign demand for US debt fades, rates and everyday costs may feel the pressure.August 8 at 1:00 AM | Behind the Markets (Ad)Cellectis (CLLS) Projected to Release Earnings on ThursdayAugust 1, 2026 | americanbankingnews.comCellectis to Report Second Quarter Financial Results on August 6, 2026July 30, 2026 | globenewswire.comProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioJuly 15, 2026 | globenewswire.comSee More Cellectis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email. Email Address About CellectisCellectis (NASDAQ:CLLS) is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors. The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies. Its pipeline includes multiple CAR‐T candidates, such as those targeting CD19 and CD22 antigens for B‐cell malignancies and other programs addressing acute myeloid leukemia. Cellectis advances these investigational therapies through preclinical research and early‐ to mid‐stage clinical trials, often in partnership with leading pharmaceutical firms to enhance development and commercialization capabilities. Cellectis operates research and process development laboratories as well as GMP manufacturing facilities across Europe and North America. Clinical trials are conducted in premier cancer centers in the United States and Europe, reflecting the company’s global reach. Strategic collaborations and licensing agreements support the expansion of its gene‐edited therapies into new indications and geographic markets, with an emphasis on scalable production and regulatory readiness. Under the leadership of founder and Chief Executive Officer Dr. André Choulika, Cellectis has established itself as a pioneer in TALEN‐based genome editing. The management team combines scientific and commercial expertise to drive innovation, with a focus on delivering next‐generation allogeneic CAR‐T therapies to patients worldwide.View Cellectis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Quantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusDatadog’s Drop Says More About Expectations Than EarningsD-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-OffAppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay BullishUber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
